TY - JOUR
T1 - Human airway epithelial cells present antigen to influenza virus-specific CD8+ CTL inefficiently after incubation with viral protein together with ISCOMATRIX®
AU - Rimmelzwaan, G. F.
AU - Boon, A. C.M.
AU - Geelhoed-Mieras, M. M.
AU - Voeten, J. T.M.
AU - Fouchier, R. A.M.
AU - Osterhaus, A. D.M.E.
PY - 2004/7/29
Y1 - 2004/7/29
N2 - In the present paper, an in vitro model was established in which the interaction between influenza virus-specific CD8+ T cells and human airway epithelial cells can be studied. To this end, the human lung epithelial cell line A549 was transduced with the HLA-A*0201 gene. This MHC class I allele is involved in the presentation of the immunodominant M158-66 cytotoxic T lymphocyte (CTL) epitope of the influenza A virus matrix protein. The A549-HLA-A2 cells and a CD8+ T cell clone specific for the M1 58-66 epitope were used to evaluate ISCOMATRIX® (IMX), which is considered a potential mucosal adjuvant for influenza vaccines, for its capacity to activate virus-specific CTL after incubation with epithelial cells. It was found that virus infected epithelial cells activated virus-specific CTL efficiently. However, incubation of epithelial cells with ISCOMATRIX® and recombinant M1 protein activated CD8+ T cells inefficiently, unlike the incubation of C1R cells expressing a HLA-A2 trans gene or HLA-A2+ B-lymphoblastoid cells with these reagents. It was concluded that this lack of antigen presentation by epithelial cells indicate that these cells are not subject to killing by virus-specific CTL upon instillation with ISCOMATRIX®-based vaccines, which may be a favorable property of mucosal vaccines.
AB - In the present paper, an in vitro model was established in which the interaction between influenza virus-specific CD8+ T cells and human airway epithelial cells can be studied. To this end, the human lung epithelial cell line A549 was transduced with the HLA-A*0201 gene. This MHC class I allele is involved in the presentation of the immunodominant M158-66 cytotoxic T lymphocyte (CTL) epitope of the influenza A virus matrix protein. The A549-HLA-A2 cells and a CD8+ T cell clone specific for the M1 58-66 epitope were used to evaluate ISCOMATRIX® (IMX), which is considered a potential mucosal adjuvant for influenza vaccines, for its capacity to activate virus-specific CTL after incubation with epithelial cells. It was found that virus infected epithelial cells activated virus-specific CTL efficiently. However, incubation of epithelial cells with ISCOMATRIX® and recombinant M1 protein activated CD8+ T cells inefficiently, unlike the incubation of C1R cells expressing a HLA-A2 trans gene or HLA-A2+ B-lymphoblastoid cells with these reagents. It was concluded that this lack of antigen presentation by epithelial cells indicate that these cells are not subject to killing by virus-specific CTL upon instillation with ISCOMATRIX®-based vaccines, which may be a favorable property of mucosal vaccines.
KW - ISCOMATRIX®
KW - Influenza virus
KW - Vaccine
UR - https://www.scopus.com/pages/publications/3142634787
U2 - 10.1016/j.vaccine.2004.01.052
DO - 10.1016/j.vaccine.2004.01.052
M3 - Article
C2 - 15246610
AN - SCOPUS:3142634787
SN - 0264-410X
VL - 22
SP - 2769
EP - 2775
JO - Vaccine
JF - Vaccine
IS - 21-22
ER -